Liquidia (LQDA) Revenue Growth (1y) (2021 - 2026)
Liquidia (LQDA) Revenue Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 2.34% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 2.91% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -11.85% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | -1.62% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 7.85% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 42.25% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 14.92% |
| 10 | Liquidia | 7.47 Bn | 7.25 Bn | 121.79 Mn | 4,158.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4,158.49% |
| Dec 31, 2025 | 3,054.65% |
| Sep 30, 2025 | 1,121.72% |
| Jun 30, 2025 | 141.51% |
| Mar 31, 2025 | 4.98% |
| Dec 31, 2024 | -35.62% |
| Sep 30, 2024 | 20.94% |
| Jun 30, 2024 | -23.55% |
| Mar 31, 2024 | -33.85% |
| Dec 31, 2023 | -15.47% |
| Sep 30, 2023 | 16.21% |
| Jun 30, 2023 | 22.15% |
| Mar 31, 2023 | 28.67% |
| Dec 31, 2022 | 66.72% |
| Sep 30, 2022 | -0.44% |
| Jun 30, 2022 | 16.05% |
| Mar 31, 2022 | 13.23% |
| Dec 31, 2021 | 334.68% |